BioTerm Pharmaceuticals · raw details

BioTerm Pharmaceuticals develops therapeutics for the prevention of preterm labor and for the induction of labor. The company has developed the patent-pending Preventerm molecule for the prevention of preterm labor and the patented Inducterm molecule for labor induction. Preventerm is designed to block three of the five factors that prepare the cervix for labor, representing an effective multistep inhibition of the enzymes that begin the labor process. By attacking metalloproteinases and cytokine precursors, Preventerm interrupts several steps in the biological pathway, thereby preventing labor for up to a week, with 90% efficacy. Inducterm works by the reverse process, providing collagenase to begin the breakdown of cervical proteins and thereby inducing labor in three to five hours. Both of the companys drugs are based on scientifically and clinically proven molecules that are safe, inexpensive, and easily administered with minimal side effects. BioTerm Pharmaceuticals is currently seeking an equity investment to broaden management and to enhance marketing and business development activities in the U.S. and Europe.